OCREVUS® (Ocrelizumab) is an immunosuppressive drug used in the treatment of Relapsing and Primary Progressive Multiple Sclerosis.
OCREVUS® is manufactured by Genentech.
Administration and Dosage:
Administration of OCREVUS® is a biweekly intravenous infusion for 2 doses followed by a 6 month maintenance dose.
Common Side Effects:
The more common side effects of OCREVUS® include infusion reactions and infections.
Please read the full Prescribing Information for OCREVUS® and discuss any questions you have with your doctor.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
OCREVUS® is indicated to treat:
- Multiple Sclerosis